Patient Case 1: Discussion
December 03, 2021

The panel continues their conversation about the first patient case.

Patient Case 1: A 65-Year-Old Man With RCC
December 03, 2021

Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.

Potential New Therapeutic Option May Combat Drug Resistance in HER2+ Breast Cancer and Ovarian Cancer
December 03, 2021

A study from the Yale Cancer Center potentially introduces a drug design platform to fight drug resistance for patients with HER2-positive breast cancer and ovarian cancer.

NCCN Reverses Guideline Recommendation, States Active Surveillance Should Be Only Option for Low-Risk Prostate Cancer
December 03, 2021

The National Comprehensive Cancer Network has reversed its previous ruling in September and instead recommends patients with low-risk prostate cancer receive active surveillance.

Presentation: Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
December 03, 2021

Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

FDA Approves Rituximab Plus Chemo for Select Pediatric Hematologic Malignancies
December 03, 2021

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

Zanubrutinib Combo Meets Primary End Point of Undetectable MRD in CLL/SLL Despite Short Treatment Duration
December 03, 2021

Patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with zanubrutinib, obinutuzumab, and venetoclax experienced increased rates of undetectable minimal residual disease in peripheral blood and bone marrow.

FDA Grants Fast Track Designation to Arfolitixorin for Treatment of Advanced Colorectal Cancer
December 03, 2021

Arfolitixorin was granted a fast track designation by the FDA for advanced colorectal cancer based on its potential to address unmet medical needs.

DNA Sequencing of Bone Marrow Is Predictive of ALL Relapse Following Treatment With Tisagenlecleucel
December 02, 2021

DNA sequencing to detect minimal residual disease and eventual relapse was more accurate than flow cytometry for adult and pediatric patients with acute lymphoblastic leukemia who have been treated with tisagenlecleucel.

Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
December 02, 2021

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.